Goldline Pharmaceutical IPO

About Goldline Pharmaceutical IPO

Check Goldline Pharmaceutical IPO Allotment Status

The Goldline Pharmaceutical IPO opens on Tuesday, May 12, 2026 and closes on Thursday, May 14, 2026. The allotment of shares will take place on Friday, May 15, 2026. The credit of shares to the demat account will take place on Monday, May 18, 2026. The initiation of refunds will take place on Monday, May 18, 2026. The listing of shares will take place on Tuesday, May 19, 2026.

The offer consists of a fresh issue component. The fresh issue will include up to 0.27 crore shares of ₹11.61 crore. The total number of shares is 27,00,000 while the aggregate amount is ₹12 crores.

Goldline Pharmaceutical IPO’s price band is set at ₹41 to ₹43 per share. The lot size for an application is 3,000. The minimum amount of investment required by a retail investor is ₹2,58,000 (6,000 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (9,000 shares), amounting to ₹3,87,000.

Goldline Pharmaceutical offers a range of products across Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. Products are manufactured through contract manufacturing based on demand estimation and client requirements. The company has the resources, experience, and network to introduce additional products.

Objectives of Goldline Pharmaceutical IPO

• Repayment of all or a portion of certain outstanding borrowings availed by the company.
  
• General corporate purposes.
  

Industry Outlook

The Indian pharmaceutical industry is the world’s 3rd largest by volume of production and plays a significant role globally. India is a global leader in the supply of DPT, BCG, and Measles vaccines and is one of the largest suppliers of low-cost vaccines in the world.

India has the highest number of United States Food and Drug Administration (USFDA)-compliant pharma plants outside of the USA. There are 500 API manufacturers contributing about 8% to the global API industry. India is the largest supplier of generic medicines, with a 20% share in the global supply, manufacturing 60,000 different generic brands across 60 therapeutic categories.

About Goldline Pharmaceutical

Goldline Pharmaceutical is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Their product portfolio is organised into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. Their customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users.

They also extend comprehensive material supply and procurement support to hospitals and healthcare partners through their promoter group entities, Numerius Healthcare Pvt Ltd (formerly known as Enrich Healthcare and PSPL International) and Activista Healthcare Pvt Ltd (formerly known as Gold N Gold Distributors). They manage trading and supply chain operations, thereby ensuring reliable procurement, seamless distribution, and logistical efficiency.

Strengths of Goldline Pharmaceutical

• Asset-light business model and competitive products.
  
• Scalable business model.
  
• Wide and diverse range of product offerings.
  
• Strong supplier and vendor relationships.
  
• Established distribution network.
  

Risks of Goldline Pharmaceutical

• Any decline in the quality of medicines manufactured or delay in the delivery of products by third-party contract manufacturers.
  
• Inability to anticipate and respond to changes in market trends and changing customer preferences in a timely and effective manner.
  
• Failure by any of their transportation providers for the procurement of their products and for the supply of their products.
  
• Any adverse change in regulations governing their products and the products of their customers.
  
• Availability of look-alikes or counterfeit healthcare products manufactured by other companies and passed off as the company’s products.
  

Source: All the financial information for listed industry peers mentioned above is on a consolidated basis sourced from the Annual Reports of the peer company or their financial results uploaded on the NSE and BSE website for the year ended March 31, 2025.

Notes: P/E Ratio has been computed based on the closing market price of equity shares on the NSE for Mono Pharmacare Limited and BSE for Chandra Bhagat Pharma Limited on April 29, 2026 divided by the Diluted EPS of March 31, 2025. RoNW is computed as net profit after tax divided by the closing net worth. Net worth has been computed as the sum of share capital and reserves and surplus. NAV is computed as the closing net worth divided by the weighted average number of equity shares.

Anchor Investor Bidding Date: Monday, May 11, 2026

Registrar: Bigshare Services Private Limited
Book Running Lead Managers: Cumulative Capital Private Limited

Business Model

The company earns its revenue through marketing pharmaceutical products under the brand name Goldline. Their product portfolio is organised into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness.

Goldline Pharmaceutical Growth Trajectory

(Restated Data) Goldline Pharmaceutical’s Total Income for FY25 was ₹28.056 crores, whereas in FY24 and FY23 it was ₹23.566 crores and ₹19.848 crores, respectively.

The Profit After Tax for FY25 was ₹2.832 crores, whereas in FY24 and FY23 it was ₹1.804 crores and ₹0.257 crores, respectively.

Their EBITDA for FY25 was ₹5.830 crores, whereas in FY24 and FY23 it was ₹4.301 crores and ₹2.194 crores, respectively.

Goldline Pharmaceutical Market Position

Presently, they maintain contractual arrangements with 15 manufacturers and 7 distributors, ensuring a stable supply chain and consistent market presence.

As of 31 March 2025, the company’s Total Income, Profit After Tax, and EBITDA were ₹28.056 crores, ₹2.832 crores, and ₹5.830 crores, respectively.

How to apply for Goldline Pharmaceutical IPO?

• Step 1: Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details. Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification. Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.